iRhythm Technologies, Inc, a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone415-632-5700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$147.29 million
Profitability
Miscellaneous
Employees748
Next Earnings Date10/29/2019 (Estimated)
OptionableOptionable
Irhythm Technologies (NASDAQ:IRTC) Frequently Asked Questions
What is Irhythm Technologies' stock symbol?
Irhythm Technologies trades on the NASDAQ under the ticker symbol "IRTC."
How were Irhythm Technologies' earnings last quarter?
Irhythm Technologies Inc (NASDAQ:IRTC) announced its quarterly earnings data on Wednesday, July, 31st. The company reported ($0.46) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.44) by $0.02. The company earned $53.30 million during the quarter, compared to the consensus estimate of $49.89 million. Irhythm Technologies had a negative net margin of 24.45% and a negative return on equity of 76.47%. The business's revenue for the quarter was up 50.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.51) EPS. View Irhythm Technologies' Earnings History.
When is Irhythm Technologies' next earnings date?
What guidance has Irhythm Technologies issued on next quarter's earnings?
Irhythm Technologies issued an update on its FY 2019 earnings guidance on Wednesday, July, 31st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $212-216 million, compared to the consensus revenue estimate of $210.3 million.
What price target have analysts set for IRTC?
8 equities research analysts have issued 12-month target prices for Irhythm Technologies' shares. Their forecasts range from $75.00 to $125.00. On average, they anticipate Irhythm Technologies' stock price to reach $101.63 in the next year. This suggests a possible upside of 47.0% from the stock's current price. View Analyst Price Targets for Irhythm Technologies.
What is the consensus analysts' recommendation for Irhythm Technologies?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Irhythm Technologies in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Irhythm Technologies.
What are Wall Street analysts saying about Irhythm Technologies stock?
Here are some recent quotes from research analysts about Irhythm Technologies stock:
- 1. According to Zacks Investment Research, "iRhythm Technologies, Inc. is a digital healthcare company. It focuses on the provision of ambulatory electrocardiogram, monitoring for patients at risk for arrhythmias primarily in the United States. The company offers ZIO Service, a platform which provides wearable biosensor with cloud-based data analytics that distill data from heartbeats into clinically actionable information. iRhythm Technologies, Inc. is headquartered in San Francisco, California. " (10/2/2019)
- 2. Northland Securities analysts commented, "We are introducing our FY20 numbers, with revs @ $263M, up 30% y/y. Our rating remains MP, but our PT changes to $75." (2/13/2019)
Has Irhythm Technologies been receiving favorable news coverage?
Media headlines about IRTC stock have been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Irhythm Technologies earned a news impact score of 0.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Irhythm Technologies.
Who are some of Irhythm Technologies' key competitors?
Some companies that are related to Irhythm Technologies include Hill-Rom (HRC), Haemonetics (HAE), Integra Lifesciences (IART), Penumbra (PEN), Globus Medical (GMED), Tandem Diabetes Care (TNDM), NuVasive (NUVA), ICU Medical (ICUI), Cantel Medical (CMD), Nevro (NVRO), Glaukos (GKOS), Cardiovascular Systems (CSII), Merit Medical Systems (MMSI), Atrion (ATRI) and Inspire Medical Systems (INSP).
What other stocks do shareholders of Irhythm Technologies own?
Who are Irhythm Technologies' key executives?
Irhythm Technologies' management team includes the folowing people:
- Mr. Kevin M. King, Pres, CEO & Director (Age 63)
- Mr. Matthew C. Garrett, Chief Financial Officer (Age 51)
- Mr. David A. Vort, Exec. VP of Sales (Age 53)
- Dr. Derrick Sung, Exec. VP of Strategy & Corp. Devel. (Age 46)
- Mr. Karim Karti, Chief Operating Officer (Age 50)
When did Irhythm Technologies IPO?
(IRTC) raised $76 million in an initial public offering on Thursday, October 20th 2016. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.
Who are Irhythm Technologies' major shareholders?
Irhythm Technologies' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include CIBC Private Wealth Group LLC (0.05%), Envestnet Asset Management Inc. (0.03%), Bailard Inc. (0.03%) and Cerebellum GP LLC (0.01%). Company insiders that own Irhythm Technologies stock include Bruce G Bodaken, David A Vort, Derrick Sung, Kevin M King, Matthew C Garrett, Merz Cathleen Noel Bairey, Raymond W Scott and Vijay K Lathi. View Institutional Ownership Trends for Irhythm Technologies.
Which major investors are selling Irhythm Technologies stock?
IRTC stock was sold by a variety of institutional investors in the last quarter, including Cerebellum GP LLC, CIBC Private Wealth Group LLC and Bailard Inc.. Company insiders that have sold Irhythm Technologies company stock in the last year include Bruce G Bodaken, David A Vort, Derrick Sung, Kevin M King, Matthew C Garrett and Merz Cathleen Noel Bairey. View Insider Buying and Selling for Irhythm Technologies.
Which major investors are buying Irhythm Technologies stock?
How do I buy shares of Irhythm Technologies?
Shares of IRTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Irhythm Technologies' stock price today?
One share of IRTC stock can currently be purchased for approximately $69.12.
How big of a company is Irhythm Technologies?
Irhythm Technologies has a market capitalization of $1.72 billion and generates $147.29 million in revenue each year. The company earns $-48,280,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis. Irhythm Technologies employs 748 workers across the globe.View Additional Information About Irhythm Technologies.
What is Irhythm Technologies' official website?
How can I contact Irhythm Technologies?
Irhythm Technologies' mailing address is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. The company can be reached via phone at 415-632-5700 or via email at [email protected]
MarketBeat Community Rating for Irhythm Technologies (NASDAQ IRTC)
MarketBeat's community ratings are surveys of what our community members think about Irhythm Technologies and other stocks. Vote "Outperform" if you believe IRTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
